Immunovant Inc. Common Stock vs MaxLinear Inc. Common Stock — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while MaxLinear Inc. Common Stock trades at $97.1 (market cap $9.74B). The key difference: MaxLinear Inc. Common Stock is the larger of the two by market cap, and MaxLinear Inc. Common Stock is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and MaxLinear Inc. Common Stock for 0 Days on average.
| IMVT | MXL | |
|---|---|---|
Market Cap | $6.62B | $9.74B |
Volume | 1,131,364 | 2,786,741 |
Sector | Health | Technology |
52-Week High | $44.96 | $128.03 |
52-Week Low | $17.03 | $13.05 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.72B | $9.83B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →MaxLinear develops analog and mixed-signal semiconductors for connectivity, communications, industrial, and data center applications.
Read more on MXL →